


WHAT IS CLAIMED IS:

1. A compound of the Formula A:



5

wherein:

- a is 0 or 1;
- 10 b is 0 or 1;
- m is 0, 1 or 2;
- n is 0, 1, 2 or 3;
- p is 0, 1 or 2;
- r is 0 or 1;
- 15 s is 0 or 1;
- t is 2, 3, 4, 5 or 6;

u, v, w and x are independently selected from: CH and N;

- 20 y and z are independently selected from: CH and N, provided that at least one of y and z is N;

R¹ is independently selected from:

- 1) (C=O)_aO_bC₁-C₁₀ alkyl,
- 25 2) (C=O)_aO_baryl,
- 3) C₂-C₁₀ alkenyl,
- 4) C₂-C₁₀ alkynyl,

- 5) $(C=O)_aOb$ heterocycll,
- 6) $(C=O)_aObC_3-C_8$ cycloalkyl,
- 7) CO_2H ,
- 8) halo,
- 5 9) CN ,
- 10) OH ,
- 11) ObC_1-C_6 perfluoroalkyl,
- 12) $Oa(C=O)_bNR^7R^8$,
- 13) $NR^c(C=O)NR^7R^8$,
- 10 14) $S(O)_mRa$,
- 15) $S(O)_2NR^7R^8$,
- 16) $NR^cS(O)_mRa$,
- 17) oxo,
- 18) CHO ,
- 15 19) NO_2 ,
- 20) $NR^c(C=O)ObRa$,
- 21) $O(C=O)ObC_1-C_{10}$ alkyl,
- 22) $O(C=O)ObC_3-C_8$ cycloalkyl,
- 23) $O(C=O)Obaryl$, and
- 20 24) $O(C=O)Ob$ -heterocycle,

said alkyl, aryl, alkenyl, alkynyl, heterocycll, and cycloalkyl optionally substituted with one or more substituents selected from R^z ;

R^2 is independently selected from:

- 25 1) $(C=O)_aObC_1-C_{10}$ alkyl,
- 2) $(C=O)_aObaryl$,
- 3) C_2-C_{10} alkenyl,
- 4) C_2-C_{10} alkynyl,
- 5) $(C=O)_aOb$ heterocycll,
- 30 6) $(C=O)_aObC_3-C_8$ cycloalkyl,
- 7) CO_2H ,
- 8) halo,
- 9) CN ,
- 10) OH ,

- 11) $O_bC_1\text{-}C_6$ perfluoroalkyl,
- 12) $O_a(C=O)_bNR^7R^8$,
- 13) $NR^c(C=O)NR^7R^8$,
- 14) $S(O)_mR^a$,
- 5 15) $S(O)_2NR^7R^8$,
- 16) $NR^cS(O)_mR^a$,
- 17) CHO ,
- 18) NO_2 ,
- 19) $NR^c(C=O)O_bR^a$,
- 10 20) $O(C=O)O_bC_1\text{-}C_{10}$ alkyl,
- 21) $O(C=O)O_bC_3\text{-}C_8$ cycloalkyl,
- 22) $O(C=O)O_b$ aryl, and
- 23) $O(C=O)O_b$ -heterocycle,

said alkyl, aryl, alkenyl, alkynyl, heterocyclyl, and cycloalkyl optionally substituted
15 with one, two or three substituents selected from R^z ;

R^3 and R^4 are independently selected from: H, $C_1\text{-}C_6$ -alkyl and $C_1\text{-}C_6$ -perfluoroalkyl, or

- 20 R^3 and R^4 are combined to form $-(CH_2)_t-$ wherein one of the carbon atoms is optionally replaced by a moiety selected from O, $S(O)_m$, $-N(R^b)C(O)-$, and $-N(COR^a)-$;

R^5 is independently selected from:

- 25 1) H,
- 2) $(C=O)O_bC_1\text{-}C_{10}$ alkyl,
- 3) $(C=O)O_bC_3\text{-}C_8$ cycloalkyl,
- 4) $(C=O)O_b$ aryl,
- 5) $(C=O)O_b$ heterocyclyl,
- 30 6) $C_1\text{-}C_{10}$ alkyl,
- 7) aryl,
- 8) $C_2\text{-}C_{10}$ alkenyl,
- 9) $C_2\text{-}C_{10}$ alkynyl,
- 10) heterocyclyl,

- 11) C₃-C₈ cycloalkyl,
- 12) SO₂R^a, and
- 13) (C=O)NR^b₂,

5 said alkyl, cycloalkyl, aryl, heterocyclyl, alkenyl, and alkynyl is optionally substituted with one or more substituents selected from R^z;

10 R⁶ is NR⁷R⁸, (C₁-C₆)alkyl, (C₁-C₆)perfluoroalkyl, (C₃-C₆)cycloalkyl, noboranyl, aryl, 2,2,2-trifluoroethyl, benzyl or heterocyclyl, said alkyl, cycloalkyl, noboranyl, aryl, heterocyclyl and benzyl is optionally substituted with one or more substituents selected from R^z;

R⁷ and R⁸ are independently selected from:

- 1) H,
- 2) (C=O)ObC₁-C₁₀ alkyl,
- 15 3) (C=O)ObC₃-C₈ cycloalkyl,
- 4) (C=O)Obaryl,
- 5) (C=O)Obheterocyclyl,
- 6) C₁-C₁₀ alkyl,
- 7) aryl,
- 20 8) C₂-C₁₀ alkenyl,
- 9) C₂-C₁₀ alkynyl,
- 10) heterocyclyl,
- 11) C₃-C₈ cycloalkyl,
- 12) SO₂R^a, and
- 25 13) (C=O)NR^b₂,

said alkyl, cycloalkyl, aryl, heterocyclyl, alkenyl, and alkynyl is optionally substituted with one or more substituents selected from R^z, or

30 R⁷ and R⁸ can be taken together with the nitrogen to which they are attached to form a monocyclic or bicyclic heterocycle with 5-7 members in each ring and optionally containing, in addition to the nitrogen, one or two additional heteroatoms selected from N, O and S, said monocyclic or bicyclic heterocycle optionally substituted with one or more substituents selected from R^z;

R^Z is selected from:

- 1) (C=O)_rOs(C₁-C₁₀)alkyl,
- 2) O_r(C₁-C₃)perfluoroalkyl,
- 3) (C₀-C₆)alkylene-S(O)_mR^a,
- 5 4) oxo,
- 5) OH,
- 6) halo,
- 7) CN,
- 8) (C=O)_rOs(C₂-C₁₀)alkenyl,
- 10 9) (C=O)_rOs(C₂-C₁₀)alkynyl,
- 10) (C=O)_rOs(C₃-C₆)cycloalkyl,
- 11) (C=O)_rOs(C₀-C₆)alkylene-aryl,
- 12) (C=O)_rOs(C₀-C₆)alkylene-heterocyclyl,
- 13) (C=O)_rOs(C₀-C₆)alkylene-N(R^b)₂,
- 15 14) C(O)R^a,
- 15) (C₀-C₆)alkylene-CO₂R^a,
- 16) C(O)H,
- 17) (C₀-C₆)alkylene-CO₂H,
- 21) C(O)N(R^b)₂,
- 20 22) S(O)_mR^a,
- 23) S(O)₂N(R^b)₂
- 21) NR^c(C=O)O_bR^a,
- 22) O(C=O)O_bC₁-C₁₀ alkyl,
- 23) O(C=O)O_bC₃-C₈ cycloalkyl,
- 25 24) O(C=O)O_baryl, and
- 25) O(C=O)O_b-heterocycle,

said alkyl, alkenyl, alkynyl, cycloalkyl, aryl, and heterocyclyl is optionally substituted with up to three substituents selected from R^b, OH, (C₁-C₆)alkoxy, halogen, CO₂H, CN, O(C=O)C₁-C₆ alkyl, oxo, and N(R^b)₂;

30

R^a is (C₁-C₆)alkyl, (C₂-C₆)alkenyl, (C₂-C₆)alkynyl, (C₃-C₆)cycloalkyl, substituted or unsubstituted aryl, (C₁-C₆)perfluoroalkyl, 2,2,2-trifluoroethyl, or substituted or unsubstituted heterocyclyl; and

R^b is H, (C₁-C₆)alkyl, substituted or unsubstituted aryl, substituted or unsubstituted benzyl, substituted or unsubstituted heterocyclyl, (C₃-C₆)cycloalkyl, (C=O)OC₁-C₆ alkyl, (C=O)C₁-C₆ alkyl or S(O)₂R^a;

5 R^c is selected from:


- 1) H,
- 2) C₁-C₁₀ alkyl,
- 3) aryl,
- 4) C₂-C₁₀ alkenyl,
- 10 5) C₂-C₁₀ alkynyl,
- 6) heterocyclyl,
- 7) C₃-C₈ cycloalkyl,
- 8) C₁-C₆ perfluoroalkyl,

15 said alkyl, cycloalkyl, aryl, heterocyclyl, alkenyl, and alkynyl is optionally substituted with one or more substituents selected from R^Z;

or a pharmaceutically acceptable salt or a stereoisomer thereof.

2. The compound according to Claim 1 of the Formula B:

20



wherein:

- 25 a is 0 or 1;
- b is 0 or 1;
- m is 0, 1 or 2;

n is 0, 1, 2 or 3;

p is 0, 1 or 2;

r is 0 or 1;

s is 0 or 1;

5

u, v, w and x are independently selected from: CH and N, provided that only one of u, v, w and x may be N;

R¹ is independently selected from:

- 10 1) (C=O)_aO_bC₁-C₁₀ alkyl,
- 2) (C=O)_aO_baryl,
- 3) C₂-C₁₀ alkenyl,
- 4) C₂-C₁₀ alkynyl,
- 5) (C=O)_aO_b heterocycl,
- 15 6) (C=O)_aO_bC₃-C₈ cycloalkyl,
- 7) CO₂H,
- 8) halo,
- 9) CN,
- 10) OH,
- 20 11) O_bC₁-C₆ perfluoroalkyl,
- 12) O_a(C=O)_bNR⁷R⁸,
- 13) NR^c(C=O)NR⁷R⁸,
- 14) S(O)_mR^a,
- 15) S(O)₂NR⁷R⁸,
- 25 16) NR^cS(O)_mR^a,
- 17) oxo,
- 18) CHO,
- 19) NO₂,
- 20) NR^c(C=O)O_bR^a,
- 30 21) O(C=O)O_bC₁-C₁₀ alkyl,
- 22) O(C=O)O_bC₃-C₈ cycloalkyl,
- 23) O(C=O)O_baryl, and
- 24) O(C=O)O_b-heterocycle,

said alkyl, aryl, alkenyl, alkynyl, heterocycl, and cycloalkyl optionally substituted

35 with one or more substituents selected from R^z;

}

R² is independently selected from:

- 1) (C=O)_aO_bC₁-C₁₀ alkyl,
- 2) (C=O)_aO_baryl,
- 5 3) C₂-C₁₀ alkenyl,
- 4) C₂-C₁₀ alkynyl,
- 5) (C=O)_aO_b heterocyclyl,
- 6) (C=O)_aO_bC₃-C₈ cycloalkyl,
- 7) CO₂H,
- 10 8) halo,
- 9) CN,
- 10) OH,
- 11) O_bC₁-C₆ perfluoroalkyl,
- 12) O_a(C=O)_bNR⁷R⁸,
- 15 13) NR^c(C=O)NR⁷R⁸,
- 14) S(O)_mR^a,
- 15) S(O)₂NR⁷R⁸,
- 16) NR^cS(O)_mR^a,
- 17) CHO,
- 20 18) NO₂,
- 19) NR^c(C=O)O_bR^a,
- 20) O(C=O)O_bC₁-C₁₀ alkyl,
- 21) O(C=O)O_bC₃-C₈ cycloalkyl,
- 22) O(C=O)O_baryl, and
- 25 23) O(C=O)O_b-heterocycle,

said alkyl, aryl, alkenyl, alkynyl, heterocyclyl, and cycloalkyl optionally substituted with one, two or three substituents selected from R²;

R⁵ is independently selected from:

- 30 1) H,
- 2) (C=O)O_bC₁-C₁₀ alkyl,
- 3) (C=O)O_bC₃-C₈ cycloalkyl,
- 4) (C=O)O_baryl,
- 5) (C=O)O_bheterocyclyl,
- 35 6) C₁-C₁₀ alkyl,

- 7) aryl,
- 8) C₂-C₁₀ alkenyl,
- 9) C₂-C₁₀ alkynyl,
- 10) heterocyclyl,
- 5 11) C₃-C₈ cycloalkyl,
- 12) SO₂R^a, and
- 13) (C=O)NR^b₂,

said alkyl, cycloalkyl, aryl, heterocyclyl, alkenyl, and alkynyl is optionally substituted with one or more substituents selected from R^z;

10 R⁶ is NR⁷R⁸, (C₁-C₆)alkyl, (C₁-C₆)perfluoroalkyl, (C₃-C₆)cycloalkyl, noboranyl, aryl, 2,2,2-trifluoroethyl, benzyl or heterocyclyl, said alkyl, cycloalkyl, noboranyl, aryl, heterocyclyl and benzyl is optionally substituted with one or more substituents selected from R^z;

15 R⁷ and R⁸ are independently selected from:

- 1) H,
- 2) (C=O)ObC₁-C₁₀ alkyl,
- 3) (C=O)ObC₃-C₈ cycloalkyl,
- 20 4) (C=O)Obaryl,
- 5) (C=O)Obheterocyclyl,
- 6) C₁-C₁₀ alkyl,
- 7) aryl,
- 8) C₂-C₁₀ alkenyl,
- 25 9) C₂-C₁₀ alkynyl,
- 10) heterocyclyl,
- 11) C₃-C₈ cycloalkyl,
- 12) SO₂R^a, and
- 13) (C=O)NR^b₂,

30 said alkyl, cycloalkyl, aryl, heterocyclyl, alkenyl, and alkynyl is optionally substituted with one or more substituents selected from R^z, or

R⁷ and R⁸ can be taken together with the nitrogen to which they are attached to form a monocyclic or bicyclic heterocycle with 5-7 members in each ring and optionally

containing, in addition to the nitrogen, one or two additional heteroatoms selected from N, O and S, said monocyclic or bicyclic heterocycle optionally substituted with one or more substituents selected from R^Z;

5 R^Z is selected from:

- 1) (C=O)_rOs(C₁-C₁₀)alkyl,
- 2) O_r(C₁-C₃)perfluoroalkyl,
- 3) (C₀-C₆)alkylene-S(O)_mR^a,
- 4) oxo,
- 10 5) OH,
- 6) halo,
- 7) CN,
- 8) (C=O)_rOs(C₂-C₁₀)alkenyl,
- 9) (C=O)_rOs(C₂-C₁₀)alkynyl,
- 15 10) (C=O)_rOs(C₃-C₆)cycloalkyl,
- 11) (C=O)_rOs(C₀-C₆)alkylene-aryl,
- 12) (C=O)_rOs(C₀-C₆)alkylene-heterocyclyl,
- 13) (C=O)_rOs(C₀-C₆)alkylene-N(R^b)₂,
- 14) C(O)R^a,
- 20 15) (C₀-C₆)alkylene-CO₂R^a,
- 16) C(O)H,
- 17) (C₀-C₆)alkylene-CO₂H,
- 18) C(O)N(R^b)₂,
- 19) S(O)_mR^a,
- 25 20) S(O)₂NR⁹R¹⁰
- 21) NRC(O)O_bR^a,
- 22) O(C=O)O_bC₁-C₁₀ alkyl,
- 23) O(C=O)O_bC₃-C₈ cycloalkyl,
- 24) O(C=O)O_baryl, and
- 30 25) O(C=O)O_b-heterocycle,

said alkyl, alkenyl, alkynyl, cycloalkyl, aryl, and heterocyclyl is optionally substituted with up to three substituents selected from R^b, OH, (C₁-C₆)alkoxy, halogen, CO₂H, CN, O(C=O)C₁-C₆ alkyl, oxo, and N(R^b)₂;

R^a is (C_1-C_6) alkyl, (C_2-C_6) alkenyl, (C_2-C_6) alkynyl, (C_3-C_6) cycloalkyl, substituted or unsubstituted aryl, (C_1-C_6) perfluoroalkyl, 2,2,2-trifluoroethyl, or substituted or unsubstituted heterocyclyl; and

5 R^b is H, (C_1-C_6) alkyl, substituted or unsubstituted aryl, substituted or unsubstituted benzyl, substituted or unsubstituted heterocyclyl, (C_3-C_6) cycloalkyl, $(C=O)OC_1-C_6$ alkyl, $(C=O)C_1-C_6$ alkyl or $S(O)_2R^a$;


R^c is selected from:

10 1) H,
 2) C_1-C_{10} alkyl,
 3) aryl,
 4) C_2-C_{10} alkenyl,
 5) C_2-C_{10} alkynyl,
 15 6) heterocyclyl,
 7) C_3-C_8 cycloalkyl,
 8) C_1-C_6 perfluoroalkyl,

said alkyl, cycloalkyl, aryl, heterocyclyl, alkenyl, and alkynyl is optionally substituted with one or more substituents selected from R^z ;

20 or a pharmaceutically acceptable salt or a stereoisomer thereof.

3. The compound according to Claim 2 of the Formula B:



25

wherein:

a is 0 or 1;

b is 0 or 1;

m is 0, 1 or 2;

n is 0, 1, 2 or 3;

5 p is 0, 1 or 2;

r is 0 or 1;

s is 0 or 1;

u, v, w and x are independently selected from: CH and N, provided that only one of u,

10 v, w and x may be N;

R¹ is independently selected from:

- 1) (C=O)_aO_bC₁-C₁₀ alkyl,
- 2) (C=O)_aO_baryl,
- 15 3) C₂-C₁₀ alkenyl,
- 4) C₂-C₁₀ alkynyl,
- 5) (C=O)_aO_b heterocyclyl,
- 6) (C=O)_aO_bC₃-C₈ cycloalkyl,
- 7) CO₂H,
- 20 8) halo,
- 9) CN,
- 10) OH,
- 11) O_bC₁-C₆ perfluoroalkyl,
- 12) O_a(C=O)_bNR⁷R⁸,
- 25 13) NR^c(C=O)NR⁷R⁸,
- 14) S(O)_mR^a,
- 15) S(O)₂NR⁷R⁸,
- 16) NR^cS(O)_mR^a,
- 17) oxo,
- 30 18) CHO,
- 19) NO₂,
- 20) NR^c(C=O)O_bR^a,
- 21) O(C=O)O_bC₁-C₁₀ alkyl,
- 22) O(C=O)O_bC₃-C₈ cycloalkyl,
- 35 23) O(C=O)O_baryl, and

24) $O(C=O)O_b$ -heterocycle,

said alkyl, aryl, alkenyl, alkynyl, heterocyclyl, and cycloalkyl optionally substituted with one or more substituents selected from R₂;

R₂ is independently selected from:

5 1) C₁-C₆ alkyl,

2) aryl,

3) heterocyclyl,

4) CO₂H,

5) halo,

10 6) CN,

7) OH,

8) S(O)₂NR⁷R⁸,

said alkyl, aryl and heterocyclyl optionally substituted with one, two or three substituents selected from R₂;

15

R₅ is independently selected from:

1) H,

2) C₁-C₁₀ alkyl,

3) aryl, and

20 4) C₃-C₈ cycloalkyl,

said alkyl, cycloalkyl and aryl is optionally substituted with one or more substituents selected from R₂;

R₆ is NR⁷R⁸, (C₁-C₆)alkyl, (C₁-C₆)perfluoroalkyl, (C₃-C₆)cycloalkyl, noboranyl,

25 aryl, 2,2,2-trifluoroethyl, benzyl or heterocyclyl, said alkyl, cycloalkyl, noboranyl, aryl, heterocyclyl and benzyl is optionally substituted with one or more substituents selected from R₂;

R₇ and R₈ are independently selected from:

30 1) H,

2) (C=O)O_bC₁-C₁₀ alkyl,

3) (C=O)O_bC₃-C₈ cycloalkyl,

4) (C=O)O_baryl,

5) (C=O)O_bheterocyclyl,

- 6) C₁-C₁₀ alkyl,
- 7) aryl,
- 8) C₂-C₁₀ alkenyl,
- 9) C₂-C₁₀ alkynyl,
- 5) 10) heterocyclyl,
- 11) C₃-C₈ cycloalkyl,
- 12) SO₂R^a, and
- 13) (C=O)NR^b₂,

10 said alkyl, cycloalkyl, aryl, heterocyclyl, alkenyl, and alkynyl is optionally substituted with one or more substituents selected from R^z, or

R^z is selected from:

- 1) (C=O)_rO_s(C₁-C₁₀)alkyl,
- 2) O_r(C₁-C₃)perfluoroalkyl,
- 15 3) (C₀-C₆)alkylene-S(O)_mR^a,
- 4) oxo,
- 5) OH,
- 6) halo,
- 7) CN,
- 20 8) (C=O)_rO_s(C₂-C₁₀)alkenyl,
- 9) (C=O)_rO_s(C₂-C₁₀)alkynyl,
- 10) (C=O)_rO_s(C₃-C₆)cycloalkyl,
- 11) (C=O)_rO_s(C₀-C₆)alkylene-aryl,
- 12) (C=O)_rO_s(C₀-C₆)alkylene-heterocyclyl,
- 25 13) (C=O)_rO_s(C₀-C₆)alkylene-N(R^b)₂,
- 14) C(O)R^a,
- 15) (C₀-C₆)alkylene-CO₂R^a,
- 16) C(O)H,
- 17) (C₀-C₆)alkylene-CO₂H,
- 30 18) C(O)N(R^b)₂,
- 19) S(O)_mR^a, and
- 20) S(O)₂NR⁹R¹⁰
- 21) NR^c(C=O)O_bR^a,
- 22) O(C=O)O_bC₁-C₁₀ alkyl,

- 23) $O(C=O)O_bC_3-C_8$ cycloalkyl,
- 24) $O(C=O)O_b$ aryl, and
- 25) $O(C=O)O_b$ -heterocycle,

5 said alkyl, alkenyl, alkynyl, cycloalkyl, aryl, and heterocyclyl is optionally substituted with up to three substituents selected from R_b , OH, (C_1-C_6) alkoxy, halogen, CO_2H , CN , $O(C=O)C_1-C_6$ alkyl, oxo, and $N(R_b)_2$;

10 R^a is (C_1-C_6) alkyl, (C_3-C_6) cycloalkyl, substituted or unsubstituted aryl, or heterocyclyl; and

15 R^b is H, (C_1-C_6) alkyl, substituted or unsubstituted aryl, substituted or unsubstituted benzyl, substituted or unsubstituted heterocyclyl, (C_3-C_6) cycloalkyl, $(C=O)OC_1-C_6$ alkyl, $(C=O)C_1-C_6$ alkyl or $S(O)_2R^a$;

20 R^c is selected from:

- 1) H,
- 2) C_1-C_{10} alkyl,
- 3) aryl,
- 4) C_2-C_{10} alkenyl,
- 25) C_2-C_{10} alkynyl,
- 6) heterocyclyl,
- 7) C_3-C_8 cycloalkyl,
- 8) C_1-C_6 perfluoroalkyl,

25 said alkyl, cycloalkyl, aryl, heterocyclyl, alkenyl, and alkynyl is optionally substituted with one or more substituents selected from R_z ;

30 or a pharmaceutically acceptable salt or a stereoisomer thereof.

4. The compound according to Claim 1 which is:


30

N-[4-(3-phenylquinoxalin-2-yl)benzyl]propane-1-sulfonamide.

5. The TFA salt according to Claim 1 which is:

N-[4-(3-phenylquinoxalin-2-yl)benzyl]propane-1-sulfonamide.


6. The compound according to Claim 1 which is selected from:



or a pharmaceutically acceptable salt or a stereoisomer thereof.

7. The TFA salt according to Claim 1 which is selected from:

5



or a stereoisomer thereof.

8. A pharmaceutical composition comprising a pharmaceutical carrier, and dispersed therein, a therapeutically effective amount of a compound of Claim 1.

9. A pharmaceutical composition comprising a pharmaceutical carrier, and dispersed therein, a therapeutically effective amount of a compound of Claim 4.

10. A pharmaceutical composition comprising a pharmaceutical carrier, and dispersed therein, a therapeutically effective amount of a compound of Claim 6.

15 11. A method of inhibiting one or more of the isoforms of Akt in a mammal which comprises administering to the mammal a therapeutically effective amount of a compound of Claim 1.

20 12. A method of inhibiting one or more of the isoforms of Akt in a mammal which comprises administering to the mammal a therapeutically effective amount of a compound of Claim 4.

25 13. A method of inhibiting one or more of the isoforms of Akt in a mammal which comprises administering to the mammal a therapeutically effective amount of a compound of Claim 6.

30 14. A method for treating cancer which comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of Claim 1.

15. A method for treating cancer which comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of Claim 4.

16. A method for treating cancer which comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of Claim 6.

5 17. A pharmaceutical composition made by combining the compound of Claim 1 and a pharmaceutically acceptable carrier.

10 18. A process for making a pharmaceutical composition comprising combining a compound of Claim 1 and a pharmaceutically acceptable carrier.

19. The composition of Claim 8 further comprising a second compound selected from:

- 15 1) an estrogen receptor modulator,
- 2) an androgen receptor modulator,
- 3) retinoid receptor modulator,
- 4) a cytotoxic agent,
- 5) an antiproliferative agent,
- 6) a prenyl-protein transferase inhibitor,
- 20 7) an HMG-CoA reductase inhibitor,
- 8) an HIV protease inhibitor,
- 9) a reverse transcriptase inhibitor,
- 10) an angiogenesis inhibitor,
- 11) a PPAR- γ agonists,
- 25 12) a PPAR- δ agonists,
- 13) an inhibitor of cell proliferation and survival signaling, and
- 14) an agent that interferes with a cell cycle checkpoint.

20. The composition of Claim 19, wherein the second compound is
30 an angiogenesis inhibitor selected from the group consisting of a tyrosine kinase inhibitor, an inhibitor of epidermal-derived growth factor, an inhibitor of fibroblast-derived growth factor, an inhibitor of platelet derived growth factor, an MMP inhibitor, an integrin blocker, interferon- α , interleukin-12, pentosan polysulfate, a cyclooxygenase inhibitor, carboxyamidotriazole, combretastatin A-4, squalamine, 6-
35 O-(chloroacetyl-carbonyl)-fumagillo, thalidomide, angiostatin and troponin-1.

21. The composition of Claim 19, wherein the second compound is an estrogen receptor modulator selected from tamoxifen and raloxifene.

5 22. A method of treating cancer which comprises administering a therapeutically effective amount of a compound of Claim 1 in combination with radiation therapy.

10 23. A method of treating or preventing cancer which comprises administering a therapeutically effective amount of a compound of Claim 1 in combination with a compound selected from:

- 15 1) an estrogen receptor modulator,
- 2) an androgen receptor modulator,
- 3) retinoid receptor modulator,
- 4) a cytotoxic agent,
- 5) an antiproliferative agent,
- 6) a prenyl-protein transferase inhibitor,
- 7) an HMG-CoA reductase inhibitor,
- 8) an HIV protease inhibitor,
- 20 9) a reverse transcriptase inhibitor,
- 10) an angiogenesis inhibitor,
- 11) a PPAR- γ agonists,
- 12) a PPAR- δ agonists,
- 13) an inhibitor of inherent multidrug resistance,
- 25 14) an anti-emetic agent,
- 15) an agent useful in the treatment of anemia,
- 16) an agent useful in the treatment of neutropenia,
- 17) an immunologic-enhancing drug,
- 18) an inhibitor of cell proliferation and survival signaling, and
- 30 19) an agent that interferes with a cell cycle checkpoint.

24. A method of treating cancer which comprises administering a therapeutically effective amount of a compound of Claim 1 in combination with radiation therapy and a compound selected from:

35 1) an estrogen receptor modulator,

- 2) an androgen receptor modulator,
- 3) retinoid receptor modulator,
- 4) a cytotoxic agent,
- 5) 5) an antiproliferative agent,
- 6) 6) a prenyl-protein transferase inhibitor,
- 7) 7) an HMG-CoA reductase inhibitor,
- 8) 8) an HIV protease inhibitor,
- 9) 9) a reverse transcriptase inhibitor,
- 10) 10) an angiogenesis inhibitor,
- 10) 11) a PPAR- γ agonists,
- 10) 12) a PPAR- δ agonists,
- 10) 13) an inhibitor of inherent multidrug resistance,
- 10) 14) an anti-emetic agent,
- 10) 15) an agent useful in the treatment of anemia,
- 15) 16) an agent useful in the treatment of neutropenia,
- 15) 17) an immunologic-enhancing drug,
- 15) 18) an inhibitor of cell proliferation and survival signaling, and
- 15) 19) an agent that interferes with a cell cycle checkpoint.

20 25. A method of treating or preventing cancer which comprises administering a therapeutically effective amount of a compound of Claim 1 and paclitaxel or trastuzumab.